Codiak Biosciences, Inc.

Codiak Biosciences, Inc.

Codiak Biosciences, Inc.

Overview
Date Founded

2015

Headquarters

500 Technology Square 9th Floor Cambridge MA 02139

Type of Company

Private

Employees (Worldwide)

1 - 10

Industries

Other Business & Consulting Services
Pharmaceuticals
Medical Support Services
Biotechnology
Holding Companies

Company Description

Codiak BioSciences, Inc. develops exosomes. It engages in the power of exosomes, therapeutic applications, diagnostic applications, and proprietary production. The company was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Codiak Biosciences, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founding President & Chief Executive Officer

Chief Financial Officer

Chief Legal Officer

Executive Vice President & Head of Research & Development

Vice President & Head of Clinical Development

Director of Science Operations

Senior Clinical Coordinator

Director of Development

Executive Vice President-Manufacturing

Board of Directors

President & Director at The Broad Institute, Inc.

Founding President & Chief Executive Officer at Codiak Biosciences, Inc.

Managing Director at ARCH Venture Partners

Faculty Director of the Deshpande Center for Technological Innovation at Massachusetts Institute of Technology

Executive Partner at Mpm Capital LLC

Co-Founder at BioCentury Publications, Inc.

Paths to Codiak Biosciences, Inc.
Potential Connections via
Relationship Science
You
Codiak Biosciences, Inc.
Recent Transactions
Details Hidden

Codiak Biosciences, Inc. raised money in a private placement transaction

Details Hidden

Codiak Biosciences, Inc. raised money in a private placement transaction

Clients

• About Us • Mission & Values • Management Team • Board of Directors • Board Committees • Commercial Capabilities • Corporate Responsibility • Ethical Sales & Marketing • Drug Safety & Medical Info • Physician Data Restriction Program • California Compliance Declaration • Stories • What’s in a Name? • Business Development • Locations ABOUT US Jazz Pharmaceuticals plc is an international specialty biopharmaceutical company dedicated to helping patients with unmet medical needs. We identify, develop and commercialize innovative products in focused therapeutic areas, with a strong commercial focus and expertise in narcolepsy, oncology, pain and psychiatry. Our marketed product portfolio includes: XYREM® (sodium oxybate), ERWINAZETM (asparaginase Erwinia chrysanthemi), PRIALT® (ziconotide) solution, intrathecal infusion, FAZACLO® (clozapine, USP) LD and HD , and LUVOX CR® (fluvoxamine maleate). The product information on XYREM, ERWINAZE, PRIALT, FAZACLO LD, FAZACLO HD and LUVOX CR is intended only for residents of the United States. For more information, including complete prescribing information and boxed warnings, click on the product names above. Please visit www.EUSAPharma.com for more information about our international division, EUSA Pharma, and our products marketed outside the U.S. We plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our unique commercial expertise. As we evaluate additional acquisition and in-licensing opportunities, we work closely with healthcare professionals and patient advocates to identify significant treatment gaps where Jazz Pharmaceuticals’ unique approach to patient care and patient-focused products may be able to bring a new therapeutic option to the market where none existed previously.

Investors
Details Hidden

FMR LLC (Fidelity Management and Research) or Fidelity Investments is an American multinational financial services corporation. It is one of the largest mutual fund and financial services groups in the world. Founded in 1946, the company has since served North American investors. Fidelity Ventures is its venture capital arm. Fidelity International Limited (FIL), was an international affiliate founded in 1969, serving most countries in the rest of the world. In September 2011, FIL was rebranded as 'Fidelity Worldwide Investment'. Fidelity Investments manages a large family of mutual funds provides fund distribution and investment advice services, as well as providing discount brokerage services, retirement services, wealth management, securities execution and clearance, life insurance and a number of other services.

Details Hidden

State of Alaska is a U.S. state situated in the northwest extremity of the North American continent. Bordering the state to the east are the Canadian territory of Yukon and the Canadian province of British Columbia; to the north is the Arctic Ocean; and to the west and south is the Pacific Ocean with Russia farther west across the Bering Strait. Alaska is the largest state in the United States by area, the 4th least populous, and the least densely populated of the 50 states in the U.S. Approximately half of Alaska’s residents live within the Anchorage metropolitan area. Its economy is dominated by the oil, natural gas, and fishing industries, resources which it has in abundance. Tourism is also a significant part of the economy. Although it had been occupied for thousands of years by indigenous people, from the 18th century onward, European powers considered the territory of Alaska ripe for exploitation and trade. The area went through several administrative changes before becoming organized as a territory on May 11, 1912. It was admitted as the 49th state of the U.S. on January 3, 1959.

Details Hidden

Flagship Pioneering focuses on investments in the following sectors: (1) therapeutics (2) life science tools and diagnostics and (3) bioenergy and clean technology. The firm looks for companies with exceptional management teams and significant commercial opportunities resulting from market discontinuities or technology breakthroughs. Flagship Ventures typically serves as lead investor. The majority of their investments are seed or first round investments. Initial investments range from $250,000 to $5 million, with typically initial investments ranging from $2.5 million to $4 million. Flagship Ventures may invest up to $15 million to $20 million over the life of a venture and typically forms syndicates that include other venture capital firms

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Codiak Biosciences, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Codiak Biosciences, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Codiak Biosciences, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/codiak-biosciences-inc-180312987
  • https://relationshipscience.com/organization/codiak-biosciences-inc-180312987